Factors associated with reporting left ventricular ejection fraction with 3D echocardiography in real‐world practice

• Published in: Echocardiography (Mount Kisco, N.Y.) Vol. 41; no. 2; pp. e15774 - n/a
• Main Authors: Faridi, Kamil F., Zhu, Zhaohan, Shah, Nimish N., Crandall, Ian, McNamara, Robert L., Flueckiger, Peter, Bachand, Karen, Lombo, Bernardo, Hur, David J., Agarwal, Vratika, Reinhardt, Samuel W., Velazquez, Eric J., Sugeng, Lissa
• Format: Journal Article
• Language: English
• Published: United States 01-02-2024
• Subjects: 3D echocardiography; left ventricular ejection fraction; quality; left ventricular ejection fraction; 3D echocardiography; quality
• ISSN: 0742-2822; 1540-8175
• DOI: 10.1111/echo.15774

Background
Guidelines recommend 3D echocardiography (3DE) to assess left ventricular ejection fraction (LVEF) on transthoracic echocardiogram (TTE) when possible, but it is unclear which factors are most strongly associated with reporting 3DE LVEF in real‐world practice.
Methods
We evaluated 3DE LVEF reporting by age, sex, BMI, TTE location and variation in reporting by sonographer and reader. All TTEs were performed without contrast enhancement agent at a large medical center from 9/2015 to 12/2020 using ultrasound machines capable of 3DE. We used multivariable logistic regression to assess which factors were most associated with reporting 3DE LVEF.
Results
Among 35 641 TTEs included in this study, 57.4% were performed on women. 3DE LVEF was reported on 18 391 TTEs (51.6% of cohort; 50.5% for women and 52.4% for men). Portable inpatient TTEs (n = 5569) had the lowest rates of 3DE LVEF reporting (30.9%), while general outpatient TTEs (n = 15 933) had greater reporting (56.9%). Outpatient TTEs with an indication for chemotherapy (n = 3244) had the highest rates of 3DE LVEF (87.2%). The median (IQR) percentage of TTEs reporting 3D LVEF was 52.7% (43.1%–68.1%) among sonographers and 51.6% (46.5%–59.6%) among readers. Among 20082 (56.3%) TTEs with 3DE LVEF measured by sonographers, 91.6% were included by readers in the final report. After adjustment, performing sonographer in the highest reporting quartile was most strongly associated with reporting 3DE LVEF (OR 7.04, 95% CI 6.55–7.56), while an inpatient portable study had the strongest negative association for reporting (OR .38, 95% CI .35–.40).
Conclusions
Use of 3DE LVEF in real‐world practice varies substantially based on performing sonographer and is low for hospitalized patients, but can be frequently used for chemotherapy. Initiatives are needed to increase sonographer 3DE acquisition in most clinical settings.